Pacific Biosciences of California, Inc. Announces First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pacific Bio (PACB) Reports In-Line Q1 EPS, Achieves Second Development Milestone
May 5, 2015 5:17 PM EDTPacific Bio (NASDAQ: PACB) reported Q1 EPS of ($0.27), in-line with the analyst estimate of ($0.27).
Pacific Biosciences of California, Inc. (Nasdaq: PACB), provider of the PacBio® RS II Sequencing System, today announced that it has achieved a second development milestone... More
